Morgan Stanley lowered the firm’s price target on Elevance Health (ELV) to $352 from $359 and keeps an Equal Weight rating on the shares. For healthcare technology and providers, the firm sees an “attractive backdrop for alpha-generation opportunities” in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing “another year of unprecedented policy, reimbursement, and utilization headwinds,” the analyst added in a year-ahead outlook note for the Healthcare Services group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $385 from $370 at BofA
- Elevance Health Appoints Amy Schulman as Independent Director
- Cantor Fitzgerald says CMS guidance reinforces 2026 as ‘difficult for Medicaid’
- Republican lawmakers have yet to agree on healthcare plan, WSJ reports
- Trump Weekly: White House postpones healthcare proposal after backlash